LY-CoV555

Category

NIAID ACTIV-3 Study Investigating LY-CoV555 & Remdesivir Placed on Pause: Drug Safety Monitoring Board Move Based on Safety Concern

The ACTIV-3 clinical trial, funded by the National Institute of Allergy and Infectious Diseases (NIAID) and a large group of collaborators, has been paused due to possible safety issues observed by the independent data safety monitoring board (DSMB). This federally...

Lilly, NIAID & Care Access Research Transform How Studies Done to Reach Nursing Homes During COVID-19 Pandemic

On Aug. 3, TrialSite applauded the effort of  Lilly & Co. (NYSE: LLY) and the National Institute of Allergy and Infectious Diseases (NIAID) for the Blaze-2 clinical trial. Why? Because it’s one of the first, if not the first nationwide intervention during the...

University of Kansas Medical Center Goes All Out in Research Contributing to Beating COVID-19 and Exiting the Pandemic

University of Kansas Medical Center (KUMC) joined the ACTIV-2 clinical trial recently, targeting those patients diagnosed with mild COVID-19 symptoms in a quest to determine how the advanced monoclonal antibody-based product developed by Eli Lilly, LY-COV555, can help...

Lilly’s Monoclonal Antibody Produces Positive Data, Company Gears up for Further Review & Inks Production Deal with Amgen

TrialSite News reported on Aug 22 that a South Texas trial site location reported growing confidence in a SARS-CoV-2 neutralizing antibody-based investigational product developed by Eli Lilly (Lilly) called LY-CoV555. Developed with the help of powerful discovery...

Pin It on Pinterest